Physician profile
David J Pompa
NPI 1114001104
$2,019.09
in general payments reported to CMS, 2019-2025
9 companies · $493 in 2025
The $493 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $531 · 2020: $93.17 · 2021: $61.42 · 2022: $125 · 2023: $326 · 2024: $389 · 2025: $493.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,209.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,208.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $595.17 | 2019-2025 | Livdelzi |
| Genzyme Corporation | $360.52 | 2022-2025 | |
| Abbvie INC. | $337.83 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $280.22 | 2019-2025 | Entyvio |
| Janssen Biotech, INC. | $149.09 | 2024-2025 | Tremfya, Stelara |
| Madrigal Pharmaceuticals | $130.59 | 2024 | Resmetirom |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $119.76 | 2019-2020 | |
| Shionogi INC | $34.33 | 2020 | |
| Dova Pharmaceuticals | $11.58 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Pompa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.